Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KIF11 | P52732 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17968861 | 0.91 | NR4A2 (0.58) | NR4A2MEN1KMT2ATP53MAPT | |
| SCHEMBL17796014 | 0.82 | GAA (0.62) | NR4A2MEN1KMT2AMAPTKDM4E | |
| SCHEMBL17792392 | 0.82 | NR4A2 (0.57) | NR4A2MEN1KMT2ATP53MAPT | |
| SCHEMBL16400952 | 0.80 | ALDH1A1 (0.57) | NR4A2MEN1KMT2ATP53MAPT | |
| SCHEMBL16401274 | 0.80 | NR4A2 (0.55) | NR4A2MEN1KMT2ATP53MAPT | |
| SCHEMBL31706267 | 0.79 | CFTR (0.52) | NR4A2MEN1KMT2ATP53MAPT | |
| SCHEMBL16410982 | 0.77 | NR4A2 (0.51) | NR4A2MEN1KMT2ATP53MAPT | |
| SCHEMBL16400953 | 0.76 | NR4A2 (0.79) | NR4A2MEN1KMT2ATP53MAPT | |
| SCHEMBL9452207 | 0.76 | KDM4E (0.57) | MEN1KMT2AMAPTKIF11KDM4E | |
| SCHEMBL24482984 | 0.74 | MEN1 (0.47) | MEN1KMT2AMAPTKIF11KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851427-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-26 | — | — | US | disclosed |
| US-20210130349-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-05-06 | — | — | US | disclosed |
| US-20210130349-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-05-06 | — | — | US | disclosed |
| US-10899756-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3022205-B1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3022205-B1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-02 | — | — | US | disclosed |
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-02 | — | — | US | disclosed |
| EP-3022205-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015009930-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015009930-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE2A, PDE3A | NR4A2 3381/4885MEN1 3763/4885KMT2A 1442/4885 |
| US-11851427-B2 | Phosphodiesterase inhibitors and uses thereof | PDE5A, PDE2A, PDE3A | NR4A2 3331/4885MEN1 3414/4885KMT2A 1299/4885 |
| US-10899756-B2 | Phosphodiesterase inhibitors and uses thereof | PDE5A, PDE2A, PDE3A | NR4A2 3331/4885MEN1 3414/4885KMT2A 1299/4885 |
| US-20210130349-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE2A, PDE3A | NR4A2 3381/4885MEN1 3763/4885KMT2A 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.